Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances

Patricia M. Danzon, Sean Nicholson, Nuno Sousa Pereira

NBER Working Paper No. 9615
Issued in April 2003
NBER Program(s):Health Economics

Using data on over 900 firms for the period 1988-2000, we estimate the effect on phase-specific biotech and pharmaceutical R&D success rates of a firm's overall experience, its experience in the relevant therapeutic category; the diversification of its experience, and alliances with large and small firms. We find that success probabilities vary substantially across therapeutic categories and are negatively correlated with mean sales by category, which is consistent with a model of dynamic, competitive entry. Returns to experience are statistically significant but economically small for the relatively straightforward phase 1 trials. We find evidence of large, positive, and diminishing returns to a firm's overall experience (across all therapeutic categories) for the larger and more complex late-stage trials that focus on a drug's efficacy. There is some evidence that a drug is more likely to complete phase 2 if developed by firms with considerable therapeutic category-specific experience and by firms whose experience is focused rather than broad (diseconomies of scope). Our results confirm that products developed in an alliance tend to have a higher probability of success, at least for the more complex phase 2 and phase 3 trials, and particularly if the licensee is a large firm.

download in pdf format
   (230 K)

email paper

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w9615

Published: Danzon, Patricia M., Sean Nicholson and Nuno Sousa Pereira. "Productivity In Pharmaceutical-Biotechnology R&D: The Role Of Experience And Alliances," Journal of Health Economics, 2005, v24(2,Mar), 317-339. citation courtesy of

Users who downloaded this paper also downloaded* these:
Danzon, Epstein, and Nicholson w10536 Mergers and Acquisitions in the Pharmaceutical and Biotech Industries
Nicholson, Danzon, and McCullough w9007 Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality
Ravenscraft and Long Paths to Creating Value in Pharmaceutical Mergers
Henderson and Cockburn w4466 Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry
Darby and Zucker w8954 Going Public When You Can in Biotechnology
NBER Videos

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email:

Contact Us